Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC S O P versus CHLOROPTIC P S O P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC S O P versus CHLOROPTIC P S O P.
CHLOROPTIC S.O.P. vs CHLOROPTIC-P S.O.P.
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Chloroptic-P S.O.P. contains prednisolone acetate and chloramphenicol. Prednisolone acetate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Chloramphenicol is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Treatment of superficial ocular infections caused by susceptible organismsOff-label: bacterial conjunctivitis, keratitis, blepharitis
Steroid-responsive inflammatory ocular conditionsBacterial infections or risk of bacterial infection in ocular inflammation
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
Adults: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily, or more frequently as needed. Not for injection.
None Documented
None Documented
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
Terminal elimination half-life: 2-4 hours (systemic); prolonged to 21-24 hours in severe hepatic impairment. Clinical context: short half-life supports 2-3 times daily dosing.
Primarily hepatic via glucuronidation; minor metabolism by reduction to aryl amines.
Prednisolone acetate: primarily hepatic via CYP3A4. Chloramphenicol: primarily hepatic via glucuronidation; also undergoes reduction to inactive metabolites.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: 50-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites; small amount via lacrimal drainage after ophthalmic administration.
15-20% bound to plasma proteins (albumin)
80-90% bound to plasma proteins (primarily albumin).
0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid
0.6-1.2 L/kg; clinical meaning: distributes into total body water, moderate tissue penetration.
Topical ophthalmic: low systemic absorption (<5%); oral: 30-50%
Ophthalmic: low systemic bioavailability (approx. 5-10%) due to nasolacrimal drainage and first-pass metabolism; oral: 50-70%.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
No dose adjustment required for hepatic impairment.
Safety and efficacy not established; use only if potential benefit outweighs risk.
Children: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily. Safety and efficacy not established for use beyond the recommended duration.
Use with caution in elderly patients due to increased risk of adverse effects; monitor intraocular pressure.
Same as adult dose. No specific adjustments required; use caution in patients with glaucoma or other ocular conditions.
Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) have been reported after topical ophthalmic use.
Chloramphenicol is associated with serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia). It should not be used when less toxic alternatives are available.
Bone marrow suppression including aplastic anemia; avoid prolonged use; monitor blood counts if used systemically; risk of superinfection; not for viral or fungal infections.
["Prolonged use may lead to ocular hypertension/glaucoma","Cataract formation","Secondary ocular infections","Delayed wound healing","Risk of bone marrow suppression with chloramphenicol","Systemic absorption possible, especially with prolonged use"]
Hypersensitivity to chloramphenicol or any component; concurrent use with drugs that suppress bone marrow; history of drug-induced blood dyscrasias.
["Hypersensitivity to prednisolone, chloramphenicol, or any component","Epithelial herpes simplex keratitis (dendritic keratitis)","Viral diseases of the cornea and conjunctiva (e.g., vaccinia, varicella)","Mycobacterial ocular infections","Fungal ocular infections","Untreated purulent ocular infections"]
Data Pending Review
Data Pending Review
No known food interactions with ophthalmic chloramphenicol. No dietary restrictions are required during use.
No known food interactions. Systemic absorption is minimal, so dietary restrictions are not necessary.
Chloroptic S.O.P. contains chloramphenicol, which crosses the placenta. First trimester: minimal data, but theoretical risk of gray baby syndrome. Second and third trimesters: associated with gray baby syndrome in neonates if administered near term due to immature hepatic glucuronidation; avoid use in pregnancy unless no alternative.
Topical ocular chloramphenicol is minimally absorbed systemically, and no teratogenic effects have been reported in humans. However, based on animal studies and theoretical risk of gray baby syndrome, use in pregnancy should be avoided unless clearly necessary. Risk cannot be ruled out; first-trimester exposure is not associated with specific malformations.
Chloramphenicol is excreted into breast milk. M/P ratio unknown. Potential for bone marrow suppression and gray baby syndrome in nursing infants. Contraindicated during breastfeeding.
Chloramphenicol is excreted into breast milk; M/P ratio unknown. Systemic absorption from ophthalmic use is low, but avoid breastfeeding or use alternative due to risk of bone marrow suppression and gray baby syndrome in nursing infants.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Caution is advised; use only if clearly needed and for shortest duration.
No dose adjustment required for topical ophthalmic use due to minimal systemic absorption. Use caution and consider alternative therapy.
Category C
Category C
CHLOROPTIC S.O.P. contains chloramphenicol, a bacteriostatic antibiotic effective against a wide range of ocular pathogens. Avoid use in patients with a history of bone marrow suppression or previous chloramphenicol-associated aplastic anemia. Prolonged use may lead to superinfection or ocular fungal infections. Monitor for signs of hypersensitivity such as conjunctival injection or eyelid edema. This formulation is a sterile ophthalmic ointment; apply a small ribbon to the lower conjunctival sac. Avoid contamination of the tube tip.
Chloroptic-P S.O.P. is a combination ophthalmic ointment containing chloramphenicol (antibiotic) and prednisolone (corticosteroid). Use with caution in patients with corneal epithelial defects or viral/fungal infections, as steroids can exacerbate these conditions. Shake well before use to ensure uniform suspension. Avoid prolonged use (>10 days) without re-evaluation due to risk of steroid-induced glaucoma or cataracts. Monitor intraocular pressure if used for extended periods.
Wash hands before and after application.Tilt head back and pull down lower eyelid to create a small pocket.Apply a small amount (about 1/2 inch) of ointment into the pocket.Close eyes gently for 1-2 minutes to allow absorption.Do not touch the tube tip to any surface, including the eye.Temporary blurring may occur; avoid driving or operating machinery until vision clears.Use for the full prescribed duration even if symptoms improve.Report any unusual bleeding, bruising, or signs of infection to your doctor.Store at room temperature away from moisture and heat.Do not share this medication with others.
Apply a small ribbon (approx. 1 cm) into the conjunctival sac, then close eyes for 1-2 minutes to spread medication.Avoid touching the tube tip to any surface, including the eye, to prevent contamination.Do not use this medication for longer than prescribed; prolonged use can increase eye pressure or cause cataracts.Inform your doctor if you have a history of glaucoma, diabetes, or herpes simplex infection of the eye.Temporary blurred vision after application is normal; avoid driving or operating machinery until vision clears.